A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer
A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer
Sponsor: Arcus Biosciences, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS7456
U.S. Govt. ID: NCT03846310
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This research study is testing two potential new drugs called AB928 and AB122. AB928 is an investigational drug that has been shown in animal studies to improve the functioning of the immune system, without causing any immune effects on its own. This research study will help us understand whether AB928, the study drug, can be safely given in combination with chemotherapy to patients with cancer. In addition, the study will look at the amount of study drug in the blood to evaluate the way the body processes the study drug (pharmacokinetics) and the way the study drug affects the growth of tumors in cancer patients (pharmacodynamics). A major purpose of this study is to find a safe dose range of AB928 that can be given to humans with cancer. A variety of human tumors express a high level of adenosine, a molecule which can leave the cells unable to carry out various immune functions. AB928 prevents adenosine from affecting immune cells, improving the functioning of the immune system. AB928 in this study will be evaluated in combination with a standard chemotherapy treatment (carboplatin/pemetrexed) with and without pembrolizumab and with AB122 combination therapy.
This study is closed
Catherine Shu, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have nonsquamous non-small cell lung cancer (NSCLC)? Yes No
Are you willing to undergo extra tests and procedures, including chemotherapy? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator